Company profile: SmartPharm
1.1 - Company Overview
Company description
- Provider of second-generation gene-encoded therapeutics, offering Gene MAbs, a DNA-based platform producing neutralizing antibodies against SARS-CoV-2 in muscle tissue for scalable, cost-effective COVID-19 protection, non-viral gene therapy for enzyme replacement in lysosomal storage diseases, and gene-encoded biologics to preserve and restore cell and tissue viability after acute myocardial infarction.
Products and services
- Cell and Tissue Restoration: Gene-encoded biologics aimed at preserving and restoring cell and tissue viability, particularly following acute myocardial infarction
- Enzyme Replacement Therapy: A non-viral gene therapy approach to treat lysosomal storage diseases by introducing genes that produce necessary enzymes within the body
- Gene MAbsâ„¢: A DNA-based platform that produces neutralizing antibodies against SARS-CoV-2 in muscle tissue, delivering a scalable and cost-effective method for COVID-19 protection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SmartPharm
Acceptys
HQ: United States
Website
- Description: Provider of human antibody therapies targeting cancer and infectious diseases, offering anti-cancer and anti-viral human antibodies for lung, pancreatic, gastric, and colon cancers. Founded in 2002 and based in Sparta, New Jersey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acceptys company profile →
Selexys Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics under development for inflammatory and thrombotic diseases, targeting the underlying disease mechanism—adhesion of white blood cells to sites of inflammation mediated by P-selectin binding; privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selexys Pharmaceuticals company profile →
Oncomatryx
HQ: Spain
Website
- Description: Provider of biopharmaceutical precision drugs and diagnostic devices targeting the tumor microenvironment and stroma. Develops antibody-drug conjugates and human-derived proteins targeting peritumoral fibroblasts, endothelial cells, and extracellular matrix. Offerings include OMTX705 (FAP-targeting ADC), DMTX invaScan (COL11A1 IHC assay), and DMTX bladderScan (FGFR3 IHC assay).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncomatryx company profile →
Achilles Therapeutics
HQ: United Kingdom
Website
- Description: Provider of patient-specific cancer immunotherapies that harness the immune system to target truncal tumor neoantigens. Offers PELEUS, an AI-powered bioinformatics platform to identify clonal neoantigens; VELOS, a manufacturing process to create clonal neoantigen-reactive T cell (cNeT) products; and cNeT cell therapies targeting multiple clonal neoantigens to treat cancer while sparing healthy tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achilles Therapeutics company profile →
Surface Oncology
HQ: United States
Website
- Description: Provider of next-generation cancer immunotherapy treatments based on proprietary insights into novel immunotherapy targets and emerging areas of cancer immuno-biology, advancing multiple preclinical programs with world-leading scientific founders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Surface Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SmartPharm
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SmartPharm
2.2 - Growth funds investing in similar companies to SmartPharm
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SmartPharm
4.2 - Public trading comparable groups for SmartPharm
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →